Study Results: MD Revolution and Cardiac Solutions Achieve 50% Reduction in 30-Day Cardiovascular Readmissions Using RevUp Remote Care Management

50% Reduction

MD Revolution, the leader in remote care management solutions for health systems and multi-specialty clinics, announced today that its partner, Cardiac Solutions achieved a 50% reduction in hospital cardiovascular readmission rates by using RevUp Remote Patient Monitoring and Chronic Care Management as part of their program.

Cardiac Solutions, a physician-owned practice in West Phoenix celebrated for its personalized treatment plans, conducted the study across 26,689 unique patients. Starting from already low readmission rates, Cardiac Solutions achieved a 7% 30-day readmission rate for patients using RevUp remote care management vs. 15% for patients not enrolled, representing a 50% reduction in readmissions for patients using RevUp remote care management.

Benefits

The study also showed sustained benefits on an annual basis, demonstrating efficacy and high cost-savings potential. Patients utilizing RevUp for one year achieved a 19% readmission rate vs 30% for patients not enrolled. This equates to one hospital readmission saved for every 10 patients enrolled in RevUp.

With the average cost of a cardiac readmission around $15,000 per patient, effective remote care monitoring and chronic care management solutions have the potential to create massive savings for patients and health systems.

Hospital readmission is disruptive to patients, caregivers, families and health systems. A readmission puts the patient at risk of additional complications, such as infection. The National Institutes of Health estimates cardiac readmission rates, including heart attacks and heart failure, to be 16-22% across all U.S. hospitals.

Kyle Williams, CEO, MD Revolution

“A 50% reduction in readmissions translates to millions in savings annually for a large health system or practice, with tremendous benefits for patients, especially those enrolled in Medicare,” said Kyle Williams, CEO, MD Revolution.

“The significant reductions in hospitalizations at 30 days and extending to one year are a powerful statement to the effectiveness of Medicare’s chronic care and remote patient monitoring programs,” said Samir Damani, M.D., Co-Founder of MD Revolution and Board-Certified Cardiologist. “The clinical impact is remarkable given that only 10 people have to be enrolled in the program to prevent a single hospital readmission. This is almost an order of magnitude greater in clinical impact than what is seen from common therapies such as statins used in millions of people in the prevention of coronary heart disease. Accordingly, anyone who qualifies should be enrolled in a chronic care management program.”

Population Health Management

“Population health management is important to us, and MD Revolution’s RevUp engagement technology and care team made a clear difference in the health of our patients.” said Christine Onstott, Director of Operations, Cardiac Solutions. “Our goal was to reach patients with chronic conditions and provide them with quality care in between their already scheduled in-office visits with cardiologists. Keeping a patient out of the hospital is good for the patient, insurance providers, and hospitals.”

For this program, Cardiac Solutions utilized MD Revolution’s full-service remote care program, including MD Revolution’s care management platform and clinical health coaching teams. Additionally, MD Revolution provides a robust technology solution for clinicians who wish to administer their own remote care programs.

MD Revolution recently hosted a webinar on addressing blind spots in patient care. The webinar underscores the problems faced by patients without access to high quality remote care. Click here to view the full webinar.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”